Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Biohaven Ltd. (BHVN) Insider Trading Activity
Healthcare • Biotechnology • 239 employees
Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. was formerly a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.
Total Value
$1,497,919.07
Total Shares
76,430
Average Trade Value
$99,861.27
Most Active Insider
Childs John W
Total Activity: $2,038,632
Largest Single Transaction
$1,042,393
by Childs John W on Dec 30, 2024
30-Day Activity
4 Transactions
Volume: 32,700 shares
Value: $996,238
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
Director
|
Mar 4, 2025 | 900 | $27,653 | 25,291 (+3.6%) | Purchase | |
|
Director
|
Mar 4, 2025 | 25,000 | $759,648 | 2,320,571 (+1.1%) | Purchase | |
|
Director
|
Mar 4, 2025 | 3,400 | $104,469 | 24,452 (+13.9%) | Purchase | |
|
Director
|
Mar 4, 2025 | 3,400 | $104,469 | 76,570 (+4.4%) | Purchase | |
|
Chief Scientific Officer
Officer
|
Jan 5, 2025 | 2,331 | $90,070 | 4,802 (-48.5%) | Payment of Exercise Price | |
|
Chief Executive Officer
Director, Officer
|
Jan 5, 2025 | 14,250 | $10,000 | 1,803,409 (+0.8%) | Exercise/Conversion | |
|
Chief Executive Officer
Director, Officer
|
Jan 5, 2025 | 6,805 | $262,945 | 1,796,604 (-0.4%) | Payment of Exercise Price | |
|
Chief Financial Officer
Officer
|
Jan 5, 2025 | 4,250 | $0 | 196,013 (+2.2%) | Exercise/Conversion | |
|
Svp, Clinical Operations
Officer
|
Jan 5, 2025 | 3,750 | $10,000 | 99,719 (+3.8%) | Exercise/Conversion | |
|
Svp, Clinical Operations
Officer
|
Jan 5, 2025 | 1,956 | $75,580 | 97,763 (-2.0%) | Payment of Exercise Price | |
|
Chief Financial Officer
Officer
|
Jan 5, 2025 | 2,561 | $98,957 | 193,452 (-1.3%) | Payment of Exercise Price | |
|
Vp, Chief Accounting Officer
Officer
|
Jan 5, 2025 | 2,500 | $0 | 66,168 (+3.8%) | Exercise/Conversion | |
|
Vp, Chief Accounting Officer
Officer
|
Jan 5, 2025 | 1,117 | $43,161 | 65,051 (-1.7%) | Payment of Exercise Price | |
|
Chief Scientific Officer
Officer
|
Jan 5, 2025 | 4,750 | $10,000 | 7,133 (+66.6%) | Exercise/Conversion | |
|
Director
|
Dec 30, 2024 | 29,000 | $1,042,393 | 2,368,741 (+1.2%) | Purchase |